SCHEMBL3525546

SCHEMBL3525546

CC(C)(C)OC(=O)Nc1ccc(-c2coc3ccnc(N)c23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.50
MAP4K4 O95819 4/20 0.48
CYP17A1 P05093 2/20 0.47
FLT1 P17948 6/20 0.46
FLT3 P36888 4/20 0.46
PLK4 O00444 3/20 0.46
ROCK2 O75116 3/20 0.46
LCK P06239 3/20 0.46
LYN P07948 3/20 0.46
RET P07949 3/20 0.46
FLT4 P35916 3/20 0.46
FRK P42685 3/20 0.46
CSNK1D P48730 3/20 0.46
BLK P51451 3/20 0.46
IRAK1 P51617 3/20 0.46
NEK2 P51955 3/20 0.46
LIMK1 P53667 3/20 0.46
CSNK1G2 P78368 3/20 0.46
MAP4K2 Q12851 3/20 0.46
STK3 Q13188 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529611 0.83 ABL1 (0.53) KDRMAP4K4CYP17A1FLT1FLT3
SCHEMBL3533819 0.80 MAP4K4 (0.46) KDRMAP4K4CYP17A1FLT1FLT3
SCHEMBL3381755 0.78 KDR (0.68) KDRMAP4K4FLT1FLT3PLK4
SCHEMBL3525709 0.76 RIPK1 (0.60) KDRMAP4K4FLT1FLT3PLK4
SCHEMBL3529762 0.76 KDR (0.72) KDRMAP4K4FLT1FLT3PLK4
SCHEMBL3530426 0.74 FLT1 (0.71) KDRMAP4K4FLT1FLT3PLK4
SCHEMBL3525522 0.74 KDR (0.66) KDRMAP4K4FLT1FLT3PLK4
SCHEMBL20370284 0.73 CYP17A1 (0.53) MAP4K4CYP17A1PSMB8MAPKAPK2
SCHEMBL3529485 0.73 KDR (0.50) KDRMAP4K4FLT1FLT3PLK4
SCHEMBL3531290 0.72 KDR (0.68) KDRMAP4K4FLT1FLT3PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885MAP4K4 40/4885CYP17A1 4563/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885MAP4K4 40/4885CYP17A1 4563/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885MAP4K4 40/4885CYP17A1 4563/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885MAP4K4 40/4885CYP17A1 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.